UCB SA (UCBJF)
OTC
Closed
Oct 7, 2026
Day's Range
236.9452 wk Range
228.94Overview - UCBJF - UCB SA
Key Statistics
Valuation
Enterprise Value
54.42B
P/E (Trailing)
‪18.83‬
Price / Sales (TTM)
‪5.45‬
Price / Book
‪3.75‬
EV / EBITDA
‪14.28‬
Profitability
Profit Margin
‪25.73%‬
Operating Margin
‪33.32%‬
Return on Assets
‪8.97%‬
Return on Equity
‪20.56%‬
Ownership
Shares Outstanding
190.66M
Float
120.15M
Held by Insiders
‪36.27%‬
Held by Institutions
‪39.25%‬
Price stats
Beta
‪0.17‬
50-Day Avg
‪261.04‬
200-Day Avg
‪289.55‬
Dividends
Payout Ratio
‪12.81%‬
Frequency
Annual
Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - UCBJF - UCB SA
Peers - UCBJF - UCB SA
Peer Comparison
Compared with companies in Biotechnology listed on OTC.
Profile Summary - UCBJF - UCB SA
About
UCB SA is a multinational biopharmaceutical company headquartered in Brussels, Belgium, founded in 1928 by Emmanuel Janssen. It specializes in developing innovative medicines for severe neurological and immunological diseases, including epilepsy, Parkinson's disease, Crohn's disease, psoriasis, and autoimmune…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
